Ken-ichi Kusakabe

Senior Director, Head of QOL Disease Chemistry

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ken-ichi Kusakabe is the Senior Director and Head of QOL Disease Chemistry at Shionogi in Japan. His research focuses on therapeutic strategies for neurodegenerative diseases, including the development of dual receptor inverse agonists and anti-amyloid-β therapies for Alzheimer’s disease. His recent publications highlight advances in drug discovery, including selective inhibitors for key targets in dementia-related psychosis and Alzheimer’s disease treatment.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Frederik Rombouts

Head of Medicinal Chemistry

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ken-ichi Kusakabe

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis

Anti-amyloid-β Antibodies and Anti-tau Therapies for Alzheimer’s Disease: Recent Advances and Perspectives

Foreword

Origin of the kinetic HDAC2-selectivity of an HDAC inhibitor

A Quantum Mechanics-Based Method to Predict Intramolecular Hydrogen Bond Formation Reflecting P-glycoprotein Recognition

JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate

Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2

Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction

Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial

Facile Construction of an Amino-1,3-Oxazine Scaffold using Burgess Reagent Under Mild Conditions

Collaborators (1)

Frederik Rombouts

Make your next move.